Market Intelligence, Clinical Progress, and High-Purity Reagents for Neurodegenerative and Immuno-Oncology Development.
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for PILRA drug discovery. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | PILRA ECD-Fc Protein HEK293 expressed (native glycosylation), High purity (>95%), Endotoxin controlled. Sequence Verified. |
View PILRA Products |
| Gene Delivery | PILRA Promise-ORF / Lentivirus Full-length ORF for stable cell line generation. Preserves native conformation for cell-based assays. |
View PILRA Products |
| Benchmark Ab | Anti-PILRA Recombinant Antibody Recombinant positive control derived from benchmark research clones. |
View PILRA Products |
| Validator | PILRA siRNA Set For target knockdown verification and specificity validation. |
View PILRA Products |
| Related Target A | PILRB Activating counterpart of PILRA. Crucial for counter-screening to ensure drug selectivity. |
View PILRB Products |
| Related Target B | CD99 Known functional ligand of PILRA/PILRB. Essential for ligand-blocking and functional assay setups. |
View CD99 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| PILRB Cross-reactivity / Off-target risk | Human PILRA and PILRB recombinant proteins available with strictly verified sequences and high purity (>95%) for differential screening. |
| Glycosylation-dependent Ligand Binding | HEK293 expression host ensures native post-translational O-glycosylation, critical for physiological CD99 and PANX1 binding assays. |
| Lack of Controls | Sequence-verified clinical benchmark antibodies (biosimilars) included for assay calibration. |
| False Positives in Cell Assays | Validated siRNA sets included for target-specific knockdown verification in primary microglia or macrophages. |
Live PILRA R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for PILRA therapeutics is intensifying, with major players shifting focus from traditional systemic immunology to neuro-immunology and myeloid checkpoint oncology. PILRA (Paired Immunoglobulin-like Type 2 Receptor Alpha) acts as an inhibitory receptor mainly expressed on myeloid cells, including microglia and macrophages. A naturally occurring genetic variant (PILRA G78R) has been shown to be highly protective against Alzheimer's disease, sparking significant interest in targeting this pathway. As first-generation therapies reach the clinic, the next wave of R&D is targeting highly selective monoclonal antibodies that can disrupt PILRA inhibitory signaling without interfering with its activating counterpart, PILRB.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Monoclonal Antibody (Antagonist) | Alector, Denali Therapeutics | Alzheimer's Disease, Neurodegeneration | Ligand-blocking assays (Requires high-purity HEK293-expressed PILRA and CD99 proteins) |
| Monoclonal Antibody (Inhibitor) | Biotech Startups, Academic Spin-offs | Solid Tumors (Myeloid Checkpoint) | Selectivity screening (Need PILRA vs PILRB counter-screening panel) |
| Gene Therapy / RNAi | RNAi Therapeutics Developers | Inflammatory Diseases | Knockdown validation (Requires sequence-verified PILRA siRNA and Lentivirus) |